PSI (Proteasome Inhibitor 1) is a potent proteasome inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas.

Solid

PSI (24 h) inhibits the proliferation of primary effusion lymphoma (PEL) cells at low nanomolar concentrations (CC₅₀s of 205, 190, 22.0, 53.0 nM FOR BJAB, Ramos, BC3, BCBL1 cells, respectively).
PSI (50 nM; 6 h) increases caspase-3/7 activity by 8-fold compared with control.
PSI (50 nM; 6 h) decreases the transcriptional activity of NF-κB by 52%.
PSI (1, 5 nM; 3 days) inhibits the growth of BC3 cells at a high concentration (5 nM).

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature or refrigerated transportation.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Saji C, et al. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells. Biochem Biophys Res Commun. 2011; 415(4):573-8.  [Information]